| Literature DB >> 22027004 |
Hee Kyoung Chung1, Sung Woo Kim, Sung June Byun, Eun Mi Ko, Hak-Jae Chung, Jae-Seok Woo, Jae Gyu Yoo, Hwi-Cheul Lee, Byoung-Chul Yang, Moosik Kwon, Soo-Bong Park, Jin-Ki Park, Kyung-Woon Kim.
Abstract
Granulocyte colony-stimulating factor (G-CSF) is a cytokine secreted by stromal cells and plays a role in the differentiation of bone marrow stem cells and proliferation of neutrophils. Therefore, G-CSF is widely used to reduce the risk of serious infection in immunocompromised patients; however, its use in such patients is limited because of its non-persistent biological activity. We created an N-linked glycosylated form of this cytokine, hG-CSF (Phe140Asn), to assess its biological activity in the promyelocyte cell line HL60. Enhanced biological effects were identified by analyzing the JAK2/STAT3/survivin pathway in HL60 cells. In addition, mutant hG-CSF (Phe140Asn) was observed to have enhanced chemoattractant effects and improved differentiation efficiency in HL60 cells. These results suggest that the addition of N-linked glycosylation was successful in improving the biological activity of hG-CSF. Furthermore, the mutated product appears to be a feasible therapy for patients with neutropenia.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22027004 DOI: 10.5483/BMBRep.2011.44.10.686
Source DB: PubMed Journal: BMB Rep ISSN: 1976-6696 Impact factor: 4.778